Optimizing AAV Outcomes: Maintenance Therapies
Bernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Andreas Kronbichler, MD
Elevating Care for Patients With Severe Renal Disease in AAV
Managing Patients With AAV in the Rheumatology Clinic
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
Mazen Hanna, MD
LDL-C Management Trends in ASCVD Patients
Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
John Russell, MD
Noel Dasgupta, MD, FACC
Sami Khella, MD
Bempedoic acid reduces adverse limb events in patients with PAD
Marc Bonaca, MD
No benefit of routine spironolactone post-MI
Sanjit Jolly, MD
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Subodh Verma, MD, PhD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Promising results with oral Lp(a) inhibitor in phase 2 trial
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Shawna Nesbitt, MD
Tirzepatide reduces HF events in patients with HFpEF and obesity
Milton Packer, MD
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Chisato Izumi, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.